Evidence map›Paper›PMID 27389713›Full record

ArticleArthritis care & research2017

Risk of Digital Vascular Events in Scleroderma Patients Who Have Both Anticentromere and Anti-Interferon-Inducible Protein 16 Antibodies.

Zsuzsanna H McMahan, Frederick M Wigley, Livia Casciola-Rosen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis care & research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. An update on autoantibodies in scleroderma.Current opinion in rheumatology · 2018
    Review
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Zsuzsanna H McMahanJohns Hopkins University School of Medicine, Baltimore, Maryland.
Frederick M WigleyJohns Hopkins University School of Medicine, Baltimore, Maryland.
Livia Casciola-RosenJohns Hopkins University School of Medicine, Baltimore, Maryland.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Phenotype-Specific Immune Responses in the Systemic VasculitidesP30AR053503 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI ROSEN, ANTONY · 2006 to 2015
$6.4M
Rheumatic Disease Sera: Probes of Disease MechanismsR01AR044684 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CASCIOLA-ROSEN, LIVIA A · 1997 to 2012
$3.7M
Mechanisms in Sjogrens SyndromeR01DE012354 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI ROSEN, ANTONY · 1998 to 2017
$3.4M
Interferons and cytotoxic lymphocytes in dermatomyositis and cutaneous lupusR56AR062615 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CASCIOLA-ROSEN, LIVIA A, FIORENTINO, DAVID FRANKLIN · 2013 to 2013
$200k
NIAMS NIH HHS L30 AR065225NIAMS NIH HHS P30 AR053503NIAMS NIH HHS R01 AR044684NIAMS NIH HHS R56 AR062615NIDCR NIH HHS R01 DE012354
6 · The paper itself

Abstract

objectiveTo evaluate whether scleroderma patients who are double-positive for anti-interferon-inducible protein 16 (anti-IFI-16) antibodies and anticentromere (anti-CENP) antibodies are at increased risk for significant digital vascular events relative to patients positive for anti-CENP antibodies alone.

methodsSera from 165 scleroderma patients who tested positive for anti-CENP antibodies upon clinical evaluation were reassayed for both anti-CENP and anti-IFI-16 antibodies using enzyme-linked immunosorbent assay testing. Patients who were positive for anti-CENP antibodies alone were then compared to patients who were double-positive for both anti-IFI-16 and anti-CENP antibodies. The association between a history of significant digital vascular events (digital pits, ischemic digital ulcers, and/or gangrene) and double-positive antibody status was examined using chi-square tests. After completion of univariate analysis, multivariable analyses were done to adjust for clinically relevant covariates.

resultsOf the 165 anti-CENP antibody positive patients, 21 (12.7%) also had anti-IFI-16 antibodies. Patients who were double-positive for anti-CENP and anti-IFI-16 antibodies were more likely to have had digital pits, ischemic digital ulcers, and/or gangrene (P = 0.03). After adjustment for clinically relevant covariates (age, cutaneous subtype, disease duration, and smoking), double-positive patients remained at significantly higher odds of having severe Raynaud's phenomenon (odds ratio 3.5 [95% confidence interval 1.1-11.1]; P = 0.03).

conclusionScleroderma patients who are double-positive for antibodies recognizing CENP and IFI-16 are significantly more likely to have significant digital vascular events during the course of their disease. This study provides further evidence that anti-CENP and anti-IFI-16 antibodies are disease biomarkers that may be used for risk stratification of vascular events in scleroderma.

Indexed as

AdultAgedAged, 80 and overAntibodies, AntinuclearAutoantibodiesBiomarkersCohort StudiesFemaleFingersHumansMaleMiddle AgedNuclear ProteinsPhosphoproteinsRetrospective StudiesRisk FactorsAntibodies, Antinuclearanticentromere antibodyAutoantibodiesBiomarkersIFI16 protein, humanNuclear ProteinsPhosphoproteins

Identifiers

PMID27389713
PMCPMC5219877
OpenAlexW2489601078

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.